Literature DB >> 27098255

The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen.

Tomoki Sasakawa1, Kenichi Masui2, Tomiei Kazama3, Hiroshi Iwasaki1.   

Abstract

PURPOSE: Rocuronium concentration prediction using pharmacokinetic (PK) models would be useful for controlling rocuronium effects because neuromuscular monitoring throughout anesthesia can be difficult. This study assessed whether six different compartmental PK models developed from data obtained after bolus administration only could predict the measured plasma concentration (Cp) values of rocuronium delivered by bolus followed by continuous infusion.
METHODS: Rocuronium Cp values from 19 healthy subjects who received a bolus dose followed by continuous infusion in a phase III multicenter trial in Japan were used retrospectively as evaluation datasets. Six different compartmental PK models of rocuronium were used to simulate rocuronium Cp time course values, which were compared with measured Cp values. Prediction error (PE) derivatives of median absolute PE (MDAPE), median PE (MDPE), wobble, divergence absolute PE, and divergence PE were used to assess inaccuracy, bias, intra-individual variability, and time-related trends in APE and PE values.
RESULTS: MDAPE and MDPE values were acceptable only for the Magorian and Kleijn models. The divergence PE value for the Kleijn model was lower than -10 %/h, indicating unstable prediction over time. The Szenohradszky model had the lowest divergence PE (-2.7 %/h) and wobble (5.4 %) values with negative bias (MDPE = -25.9 %). These three models were developed using the mixed-effects modeling approach. The Magorian model showed the best PE derivatives among the models assessed.
CONCLUSIONS: A PK model developed from data obtained after single-bolus dosing can predict Cp values during bolus and continuous infusion. Thus, a mixed-effects modeling approach may be preferable in extrapolating such data.

Entities:  

Keywords:  Drug delivery; Neuromuscular blocking agent; Pharmacokinetics; Rocuronium

Mesh:

Substances:

Year:  2016        PMID: 27098255     DOI: 10.1007/s00540-016-2174-5

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  21 in total

1.  Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium.

Authors:  D M Maybauer; G Geldner; M Blobner; F Pühringer; R Hofmockel; C Rex; H F Wulf; L Eberhart; C Arndt; M Eikermann
Journal:  Anaesthesia       Date:  2007-01       Impact factor: 6.955

2.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 3.  Monitoring neuromuscular block: an update.

Authors:  T Fuchs-Buder; J-U Schreiber; C Meistelman
Journal:  Anaesthesia       Date:  2009-03       Impact factor: 6.955

4.  The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data.

Authors:  Kenichi Masui; Richard N Upton; Anthony G Doufas; Johan F Coetzee; Tomiei Kazama; Eric P Mortier; Michel M R F Struys
Journal:  Anesth Analg       Date:  2009-10-27       Impact factor: 5.108

5.  The pharmacokinetics of propofol in children using three different data analysis approaches.

Authors:  B K Kataria; S A Ved; H F Nicodemus; G R Hoy; D Lea; M Y Dubois; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

6.  Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.

Authors:  Christopher Rex; Stefanie Wagner; Claudia Spies; Jens Scholz; Henk Rietbergen; Marten Heeringa; Hinnerk Wulf
Journal:  Anesthesiology       Date:  2009-07       Impact factor: 7.892

7.  Effective concentration 50 for propofol with and without 67% nitrous oxide.

Authors:  J A Davidson; A D Macleod; J C Howie; M White; G N Kenny
Journal:  Acta Anaesthesiol Scand       Date:  1993-07       Impact factor: 2.105

8.  Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients.

Authors:  J A Alvarez-Gomez; M E Estelles; J Fabregat; F Perez; A J Brugger
Journal:  Eur J Anaesthesiol Suppl       Date:  1994

9.  Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure.

Authors:  R A Cooper; V R Maddineni; R K Mirakhur; J M Wierda; M Brady; K T Fitzpatrick
Journal:  Br J Anaesth       Date:  1993-08       Impact factor: 9.166

10.  Evaluation of the predictive performance of a pharmacokinetic model for propofol in Japanese macaques (Macaca fuscata fuscata).

Authors:  T Miyabe-Nishiwaki; K Masui; A Kaneko; K Nishiwaki; T Nishio; H Kanazawa
Journal:  J Vet Pharmacol Ther       Date:  2012-05-08       Impact factor: 1.786

View more
  3 in total

1.  Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models.

Authors:  Kenichi Masui; Sayaka Ishigaki; Atsuko Tomita; Hiroshi Otake
Journal:  J Anesth       Date:  2018-08-11       Impact factor: 2.078

2.  Rocuronium bromide: clinical application of single-dose pharmacokinetic models to continuous infusion.

Authors:  Yutaka Oda
Journal:  J Anesth       Date:  2017-08-21       Impact factor: 2.078

3.  Evaluation of pharmacokinetic models of intravenous dexmedetomidine in sedated patients under spinal anesthesia.

Authors:  Shinju Obara; Tsuyoshi Imaizumi; Takahiro Hakozaki; Atsuyuki Hosono; Yuzo Iseki; Norie Sanbe; Masahiro Murakawa
Journal:  J Anesth       Date:  2017-11-02       Impact factor: 2.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.